ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2738

A Randomized Phase 3 Trial Evaluating the Safety and Efficacy of Avacopan in Patients with New or Relapsing Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Peter A. Merkel1, David Jayne2, Thomas J. Schall3, Pirow Bekker3 and Jan Hillson3, 1Division of Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 2Department of Medicine, University of Cambridge, Cambridge, United Kingdom, 3ChemoCentryx, Mountain View, CA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: ANCA, clinical trials and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Vasculitis – ANCA-Associated Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

A Randomized Phase 3 Trial Evaluating the Safety and Efficacy of Avacopan in Patients with New or Relapsing Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Peter A. Merkel1, David Jayne2, Thomas J. Schall3, Pirow Bekker3, Jan Hillson3

1. University of Pennsylvania, Philadelphia PA, USA; 2. University of Cambridge, Cambridge UK; 3. ChemoCentryx Inc., Mountain View CA, USA

Background/Purpose: Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is a potentially life-threatening systemic autoimmune disease characterized by relapses and remissions.  Treatment to induce remission usually includes high-dose glucocorticoids in combination with rituximab (RTX) or cyclophosphamide (CYC), followed by less intensive treatment to prevent relapse.  The overall burden of disease remains high, with progressive organ system damage and morbidity attributable to therapy.  High-dose glucocorticoids are associated with increased risk of infection, metabolic syndrome, bone loss, and an overall negative impact on health-related quality of life (HRQoL).  There is a need for less toxic treatment alternatives for AAV.  Avacopan (previously CCX168) is a novel, orally bioavailable, highly-selective antagonist of the human C5a receptor that has demonstrated promising efficacy and a favorable safety profile when administered for 12 weeks in Phase 2 studies of patients with active AAV (NCT0136388 and NCT02222155).

Methods: The ongoing ADVOCATE trial (NCT02994927) is a double-blind, parallel-arm, active-comparator randomized trial comparing avacopan vs. high-dose glucocorticoids in patients (age ≥ 12 years) with AAV, when co-administered with either 1) RTX OR 2) CYC followed by azathioprine or mycophenolate mofetil, for up to 1 year (Figure).  The choice of RTX vs CYC is based on investigator judgement.  Patients are stratified by: i) intended use of RTX vs CYC, ii) ANCA type (PR3-ANCA vs MPO-ANCA), and iii) newly-diagnosed vs relapsing disease.

The primary trial endpoints are 1) the proportion of patients in remission at week 26 based on BVAS=0 (Birmingham Vasculitis Activity Score) and not taking glucocorticoids; and 2) the proportion of patients who sustain remission from week 26 through week 52. HRQoL will also be assessed in patients through 52 weeks which will add to the understanding of the patient experience in AAV.  Other endpoints include adverse events, requirement for rescue medication, markers of renal disease, the Glucocorticoid Toxicity Index, and the Vasculitis Damage Index.

Results: Planned enrollment is ~300 patients from 230 sites in 20 countries, and is expected to be completed in mid-2018.  Details of the study design, outcome measures, and baseline patient data will be presented.

Conclusion: The ADVOCATE trial is unique in seeking to advance a nearly glucocorticoid-free induction regimen for AAV and has the potential to have a substantial impact on the approach to treatment of this rare disease.


Disclosure: P. A. Merkel, Bristol-Myers Squibb, 2,ChemoCentryx, 2, 5,Genentech, Inc., 2, 5,InnfaRx, 5,Insmed, 5,AbbVie Inc., 5,CaridianBCT, 2, 5,GlaxoSmithKline, 2, 5,Kypha, 2,Kiniksa, 5,Boeringher-Ingelheim, 2, 5; D. Jayne, Chemocentryx, GlaxoSmithKline, Sanofi, Roche, 2,Boehringer-Ingelheim, Astra-Zeneca, AbbVie, CSL, InflaRx, Bristol-Myers Squibb, Takeda, 5,Aurinia, 6; T. J. Schall, ChemoCentryx, 1, 3, 4; P. Bekker, ChemoCentryx, 1, 3; J. Hillson, ChemoCentryx, 1, 3,Bristol-Myers Squibb, 1.

To cite this abstract in AMA style:

Merkel PA, Jayne D, Schall TJ, Bekker P, Hillson J. A Randomized Phase 3 Trial Evaluating the Safety and Efficacy of Avacopan in Patients with New or Relapsing Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/a-randomized-phase-3-trial-evaluating-the-safety-and-efficacy-of-avacopan-in-patients-with-new-or-relapsing-anti-neutrophil-cytoplasmic-antibody-associated-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-randomized-phase-3-trial-evaluating-the-safety-and-efficacy-of-avacopan-in-patients-with-new-or-relapsing-anti-neutrophil-cytoplasmic-antibody-associated-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology